Table 1 Baseline characteristics of participants.

From: Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

 

Mepolizumab

Omalizumab

N

18

21

Age in years, mean (SD)

55.9 (12.0)

45.2 (15.2)

Female, n (%)

13 (72)

18 (86)

White race, n (%)

13 (72)

19 (91)

Current smoker, n (%)

1 (5.6)

0 (0.0)

Former smoker, n (%)

5 (27.8)

3 (14.3)

BMI, kg/m2; mean (SD)

30.5 (7.3)

29.4 (8.0)

Baseline annualized exacerbation rate, mean (SD)

3.0 (1.9)

2.1 (1.6)

Baseline pre-bronchodilator FEV1, L; mean (SD)

2.0 (0.85)

2.5 (0.85)

Baseline pre-bronchodilator FEV1% predicted, mean (SD)

70 (23)

86 (20)

Peripheral blood eosinophil counts, cells/µL; median [IQR]a

  

At biologic initiation

244 [69–362]

126 [72–280]

Maximum count in the 3 years before therapy initiation

600 [381–1210]

220 [90–335]

Immunoglobulin E (IgE), IU/µL; median [IQR]a

215 [50–482]

87 [38–266]

Allergic rhinitis, n (%)

15 (83)

21 (100)

Atopic dermatitis, n (5)

0 (0)

0 (0)

COPD, n (%)

1 (6)

0 (0)

  1. BMI, Body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; IQR, interquartile range; SD, standard deviation.
  2. aOne omalizumab user was missing baseline blood eosinophil counts and one mepolizumab user with missing baseline IgE.
Back to article page